Management of C. difficile Infection

Clinical Context and Diagnostic Interpretation

The World Journal of Emergency Surgery guidelines emphasize that diagnosis should be based on clinical signs and symptoms in combination with laboratory tests, not laboratory results alone, for patients with C. difficile infection 1, 2
Colonization is defined as the presence of the organism without disease, characterized by no diarrhea or symptoms, whereas active infection is marked by diarrhea with clinical symptoms 1
For patients with C. difficile positive but toxin-negative results, the presence of diarrhea (≥3 unformed stools in 24 hours) represents likely active CDI that requires treatment, not symptom suppression with antimotility agents 1, 2

NAAT testing, which detects toxin genes, is highly sensitive and may detect colonization, highlighting the importance of clinical context in diagnosis 2
Testing should only be performed on diarrheal stools from symptomatic patients, as testing formed stool can result in false positives representing colonization rather than infection 1, 2

A positive NAAT with negative toxin EIA in a symptomatic patient should still be treated as CDI based on clinical context, with treatment options including oral vancomycin or fidaxomicin 1, 2
Asymptomatic patients with positive C. difficile test results likely represent colonization, not infection, and do not require treatment 1, 2
The use of antimotility agents, such as loperamide, is contraindicated in patients with suspected or confirmed CDI who have active diarrhea, as it can prevent clearance of toxins and bacteria from the colon, potentially worsening the infection 2

For patients with a positive C. difficile stool test, the Infectious Diseases Society of America recommends assessing disease severity to guide treatment, with criteria including stool frequency, signs of severe colitis, and white blood cell count 3, 4
Non-severe CDI is characterized by stool frequency < 4 times daily, no signs of severe colitis, and white blood cell count < 15 × 10^9/L 3, 4
Severe CDI is characterized by fever, rigors, hemodynamic instability, signs of peritonitis, ileus, marked leukocytosis, rise in serum creatinine, elevated serum lactate, or pseudomembranous colitis on endoscopy 4

The American College of Gastroenterology recommends oral vancomycin 125 mg four times daily for 10 days for severe CDI and oral metronidazole 500 mg three times daily for 10 days for non-severe CDI 3, 4
For second or subsequent recurrence treatment, the Infectious Diseases Society of America recommends vancomycin 125 mg four times daily orally for at least 10 days or fidaxomicin 200 mg twice daily for 10 days 4, 5, 6

Colectomy should be considered for patients with perforation of the colon, systemic inflammation and deteriorating clinical condition not responding to antibiotic therapy, toxic megacolon, or severe ileus 4
The Society for Healthcare Epidemiology of America recommends avoiding antiperistaltic agents and opiates, and discontinuing proton pump inhibitors if not medically necessary 4, 7